Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Quince_Therapeutics,_Inc.
|
| gptkbp:acquisitionYear |
2022
|
| gptkbp:focusesOn |
gptkb:Alzheimer's_disease
neurodegenerative diseases |
| gptkbp:founded |
2012
|
| gptkbp:founder |
gptkb:Stephen_Dominy
gptkb:Casey_Lynch |
| gptkbp:headquarters_location |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cortexyme, Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:lead_drug_candidate |
atuzaginstat (COR388)
|
| gptkbp:leader |
gptkb:Casey_Lynch_(CEO)
Stephen Dominy (Chief Scientific Officer) |
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:notableEvent |
FDA placed clinical hold on atuzaginstat in 2021
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockSymbol |
gptkb:CRTX
|
| gptkbp:studiedBy |
bacterial causes of Alzheimer's disease
|
| gptkbp:website |
https://www.cortexyme.com/
|
| gptkbp:bfsParent |
gptkb:CTX
|
| gptkbp:bfsLayer |
6
|